The post Moderna, BioNTech rise as vaccine advisory panel backs off mRNA vaccine threat appeared first on Up2info.com.

Management View

• CEO Ugur Sahin highlighted that BioNTech maintained its leadership in the COVID vaccine market, launching a variant-adapted vaccine in partnership with Pfizer, now distributed in over 180 countries with more than 50% market

The post Biontech outlines €2B–€2.3B revenue target for 2026 while advancing late-stage oncology pipeline and leadership transition appeared first on Up2info.com.

Additionally, BNTX said that its board has initiated an executive search to find successors to founders CEO Ugur Sahin and medical chief Özlem Türeci, who are departing the company by the end of 2026 to manage a newly formed firm focused on mRNA technology.

The German-based company projected €2.0B – €2.3B in revenue for 2026 compared to €2.75B in FactSet consensus, indicating a ~22% YoY decline at the midpoint compared to its last year’s revenue figure of €2.8B.

As for Q4 results, BioNTech (BNTX) reported €907.4M in revenue with a ~24% YoY decline as lower demand for COVID-19 vaccines hurt Comirnaty sales. However, for the full year, the company posted €2.9B in revenue, indicating ~4% YoY growth, mainly due to collaboration revenue from its partner Bristol Myers Squibb (BMY), which boosted its Q3 topline.

BNTX swung to a net loss of €305.0M during Q4 compared to a €259.5M net profit in the prior-year period amid a ~127% YoY growth in other operating expenses, which included charges related to legal settlements.

Looking ahead, the company projected €2.2B – €2.5B in adjusted R&D expenses, indicating a ~16% YoY growth at the midpoint.

The post BioNTech falls on outlook, departure of co-founders appeared first on Up2info.com.

The post BioNTech Non-GAAP EPS of -€0.33, revenue of €907.4M appeared first on Up2info.com.

The post BioNTech Q4 2025 Earnings Preview appeared first on Up2info.com.

The meeting, which was initially scheduled to take place from Feb. 25 to 27, was postponed to Mar. 18–Mar. 19 this week, after several leading medical groups in the U.S. filed a lawsuit seeking a ruling to block the CDC from holding it.

According to the Federal Register, the meeting scheduled from 8 am ET to 5 pm ET on Mar. 18 and Mar. 19 will include discussions and potentially votes on COVID-19 vaccine injuries and long COVID.

The CDC’s recent scrutiny of COVID-19 vaccine injuries comes as the Health and Human Services Secretary Robert F. Kennedy Jr. looks to revamp the National Vaccine Injury Compensation Program.

Earlier this year, it was reported that RFK Jr. had prematurely ended the terms of at least four members of the Advisory Commission on Childhood Vaccines. The eight-member panel makes recommendations on vaccines and conditions to be added to the Vaccine Injury Compensation Program.

COVID-19 vaccine developers: Pfizer (PFE)/BioNTech (BNTX), Moderna (MRNA), and Novavax (NVAX).

The post CDC advisory meeting in March to focus on COVID-19 vaccine injuries, long COVID appeared first on Up2info.com.

The meeting of the CDC Advisory Committee on Immunization Practices (ACIP) which was previously set to take place from Feb. 26 to 26, will now be held at some point in mid-March, the person said. An exact date for the meeting is not finalized yet, according to the person.

The CDC, or its parent agency, the U.S. Department of Health and Human Services, declined to respond to Bloomberg’s requests for comment.

The report comes after several leading medical groups urged a federal judge in Boston on Friday to bar the CDC from holding its next ACIP meeting, citing, among other things, RFK Jr.’s decision to handpick the committee members last year.

The post CDC said to delay vaccine panel meeting after lawsuit challenging its composition appeared first on Up2info.com.

The post Pediatrics group defies CDC, endorses COVID, flu shots for children appeared first on Up2info.com.

The appointees are Adam Urato, a specialist in maternal-fetal medicine, and Kimberly Biss, a fellow of the American College of Obstetricians and Gynecologists whose publications include research on COVID-19 vaccine safety during pregnancy.

“Dr. Urato and Dr. Biss bring the scientific credentials, clinical experience, and integrity this committee requires,” RFK Jr. said in a statement.

The ACIP panel, which can include up to 19 members, meets three times a year to issue non-binding recommendations to the CDC regarding U.S. immunization policy. Their views play a key role in determining which vaccines are covered by health insurers at zero cost to the American public.

Secretary Kennedy fired all 17 ACIP members in June 2025, citing conflicts of interest and other concerns. He later appointed eight new members, and subsequently, one member withdrew from the committee just ahead of its June 25–26 meeting.

Just ahead of the ACIP’s Sept. 18–19 meeting, Kennedy named five new members to the panel, expanding it to 12.

Leading vaccine makers: Pfizer (PFE), AstraZeneca (AZN), Merck (MRK), GSK (GSK), Sanofi (SNY) (SNYNF), Moderna (MRNA), BioNTech (BNTX), and Novavax (NVAX)

The post HHS secretary RFK Jr. adds two new members to CDC vaccine panel appeared first on Up2info.com.

The post BioNTech eyes catalyst-rich 2026 as it advances multi-product oncology strategy appeared first on Up2info.com.